| Literature DB >> 30450265 |
Nitinchandra Dahyabhai Patel1, Joshua D Sieber1,2, Sergei Tcyrulnikov3, Bryan J Simmons4, Daniel Rivalti1,5, Krishnaja Duvvuri6, Yongda Zhang1, Donghong A Gao1, Keith R Fandrick1, Nizar Haddad1, Kendricks So Lao7, Hari Prasad Reddy Mangunuru1,5, Soumik Biswas1, Bo Qu1, Nelu Grinberg1, Scott Pennino8, Heewon Lee1, Jinhua J Song1, B Frank Gupton5, Neil K Garg4, Marisa C Kozlowski3, Chris H Senanayake1,9.
Abstract
Metal-catalyzed cross-coupling reactions are extensively employed in both academia and industry for the synthesis of biaryl derivatives for applications to both medicine and material science. Application of these methods to prepare tetra-ortho-substituted biaryls leads to chiral atropisomeric products that introduces the opportunity to use catalyst-control to develop asymmetric cross-coupling procedures to access these important compounds. Asymmetric Pd-catalyzed Suzuki-Miyaura and Negishi cross-coupling reactions to form tetra-ortho-substituted biaryls were studied employing a collection of P-chiral dihydrobenzooxaphosphole (BOP) and dihydrobenzoazaphosphole (BAP) ligands. Enantioselectivities of up to 95:5 and 85:15 er were identified for the Suzuki-Miyaura and Negishi cross-coupling reactions, respectively. Unique ligands for the Suzuki-Miyaura reaction vs the Negishi reaction were identified. A computational study on these Suzuki-Miyaura and Negishi cross-coupling reactions enabled an understanding in the differences between the enantiodiscriminating events between these two cross-coupling reactions. These results support that enantioselectivity in the Negishi reaction results from the reductive elimination step, whereas all steps in the Suzuki-Miyaura catalytic cycle contribute to the overall enantioselection with transmetalation and reductive elimination providing the most contribution to the observed selectivities.Entities:
Keywords: Palladium; asymmetric; catalysis; cross-coupling; phosphines
Year: 2018 PMID: 30450265 PMCID: PMC6234982 DOI: 10.1021/acscatal.8b02509
Source DB: PubMed Journal: ACS Catal Impact factor: 13.084